Conclusion
Until recently, traditional teaching has been to discontinue MAOI therapy two to three weeks before surgery. The literature and texts relating to the concurrent use of MAOI’s with anaesthesia are confusing, outdated and often contradictory. Significant adverse drug reactions can and have occurred in a minority of patients receiving MAOI’s. The true incidence of such reactions is unknown. While there are several recent clinical reports indicating the safety of these agents in combination with anaesthesia, only small numbers of patients are described in each series. Until it is possible to define those individual patients in whom adverse reactions are likely to occur, all patients must be assumed to be at some level of potential risk.
However, assuming administration in appropriate doses and for appropriate indications, patients can and likely should continue to receive MAOI therapy. A final decision on the administration of anaesthesia in the presence of MAOI therapy can only be made by an anaesthetist familiar with the pharmacology of the MAO system and its inhibitors.
Article PDF
Similar content being viewed by others
References
Zisoo kS. Side effects of isocarboxazid. J Clin. Psych 1984; 45: 53–8.
Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969; 21: 263–8.
Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest 1952; 21: 3.
Zeller EA, Barsky J, Fouts JR, Kircheimer WF, Van Orden LS. Influence of isonicotinic and hydrazine (INH) and l-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experentia (Basel) 1952; 8: 349–50.
Kline NS. Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol 1958; 19: 72–8.
Goldberg LI. Monoamine oxidase inhibitors: adverse reactions and possible mechanisms. JAMA 1964; 190: 132–8.
Sheehan DV, Claycomb JB. The use of MAO inhibitors in clinical practice.In: Psychiatric Medicine Update, Manschreck TC, Murray GB (Eds). Massachusetts General Hospital reviews for physicians, New York, Elsevier 1984; 143–62.
Biel H. Monoamine oxidase inhibitor antidepressants. Structure activity relationships.In: Principles of Psychopharmacology, Clark WG, Del Guidice J (Eds). New York: Academic Press 1970; 269–78.
Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between MAO inhibitors and foodstuffs. Br J Psychiatry 1967; 113: 349–65.
Singer TP, Van Korff RW, Murphy DL. Monoamine oxidase: structure, function and altered functions. New York: Academic Press 1979; 477–96.
Murphy DL, Garrick NA, Aulakh CS, Cohen RM. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psych 1984; 45: 37–43.
Johnston JP. Some observations upon a new monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–97.
Cantham RM, Pintar JE, Haseltine FP et al. Differences in the structure of A and B forms of human monoamine oxidase. J Neurochem 1981; 37: 363–72.
Brown GK, Powell JF, Craig TW. Molecular weight differences between human platelet and placental monoamine oxidase. Biochem Pharmacol. 1980; 29: 2595–603.
Denny RM, Fritz RR Patel NT et al. Human liver MAO-A and MAO-B separated by immunoaffinity chromatography with MAO-B-specific monoclonal antibody. Science 1982 215: 1400–3.
Tipton KF,Fowler CJ,Houslay MD, Specificities of the two forms of monoamine oxidase.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982; 87-99.
Suzuki O,Katsumata Y,Oya H. Substrate specificity of type A and type B monoamine oxidase.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Usdin E, Nagatsu T (Eds). 1982; 74–86.
Fowler CJ, Ross SB. Selective inhibitors of monoamine oxidase A and B; biochemical, pharmacological and clinical properties. Med Res Reviews 1984; 4: 323–58.
Lewinsohn R, Glover V, Sandler M, Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol 1980; 29: 1221–30.
Glover V, Sandler M. Clinical chemistry of monoamine oxidase. Cell Biochem. Funct 1986; 4: 89–97.
Schnaitman C, Erwin VG, Greenawalt JW. The submitochondrial localisation of monoamine oxidase. J Cell Biol 1967; 32: 719–35.
Blaschko H. The natural history of amine oxidases. Physiol Biochem Pharmacol 1974; 70: 83–148.
Glover V, Sandler M. Clinical chemistry of monoamine oxidase. Cell Biochem. Funct 1986; 4: 89–97.
Schildkrant JI. The catecholamine hypothesis of affective disorders. A review of the supporting evidence. Am J Psychiatry 1963; 122: 509–22.
Neff NH, Costa E. The influence of monoamine oxidase inhibition on catecholamine synthesis. Life Sciences 1966; 5: 951–8.
Lin RC, Neff NH, Nga SH et al. Turnover rates of serotonin and norepinephrine in brain of normal and pargyline-treated rats. Life Sciences 1969; 8: 1077–84.
Kapin IJ. False transmitters revisited: their role in the hypotensive action of MAO inhibitors.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982.
Finberg JPM. Effects of selective inhibition of MAO types A and B on peripheral sympathetic function.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982.
Aghajanian GK. Influence of drugs on the firing of serotonin-containing neurons in brain. Fed Proc Am Soc Exp Biol 1972; 31: 91–6.
Campbell IC, Murphy DL, Gallager DW et al. Neurotransmitter related adaption in the central nervous system following chronic monoamine oxidase inhibition.In: Monoamine oxidase: structure, function and altered functions. Singer TP, Von Korff RW, Murphy DL (Eds). New York, Academic Press 1979.
Cohen RM, Anlakh CS, Campbell K et al. Functional subsensitivity of a-adrenoreceptors accompanies reductions in yohimbine binding after clorgyline treatment. Eur J Pharmacol 1982; 81: 145–8.
Simpson GM, White K. Tyrarnine studies and the safety of MAOI drugs. J Clin Psychiatry 1984; 45: 59–61.
Mann JJ, Aarons SF, Frances AJ, Brown RD. Studies of selective and reversible monoamine oxidase inhibitors. J Clin Psychiatry 1984; 45: 62–6.
Lader MH, Sakalis G, Tansella M. Interaction between sympathetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 1972; 18: 118–23.
Pare CMB. The present status of monoamine oxidase inhibitors. Brit J Psychiatry 1985; 146: 576–84.
Birkmayer W, Riederer P, Yondim MBH. (-)deprenyl in the treatment of Parkinson’s disease. Clin Neuropharmac 1982; 5: 195–230.
Elsworth JD, Glover V, Reynolds GP et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect.” Psychoparmacology 1978; 57: 33–8.
Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson’s disease. J Neural Transmission 1978; 43: 177–98.
Richards LE, Burger A. Mechanism-based inhibitors of monoamine oxidase. Prog Drug Res 1987; 30: 205–19.
Benedetti MS, Boucher T, Carlsson A, Fowler CJ. Intestinal metabolism of tyrarnine by both forms of monoamine oxidase in the rat. Biochem Pharmacol 1983; 32: 47–52.
Hedley ED, Snyder SH. Relationship between the action of monoamine oxidase inhibition on the noradrenaline uptake system and their antidepressant efficacy. Nature 1968; 220: 1330–1.
LaRoche MJ, Brodie BB. Lack of relationship between inhibition of monoamine oxidase and potentiation of hexobarbital hypnosis. J Pharmacol Exp Ther 1960; 130: 134–7.
Bowman WC, Rand MJ. A Textbook of Pharmacology (2nd ed). Blackwell Scientific Publications, Oxford 1980; 11. 7–11.11.
Mantle TJ, Tipton KF, Garrett NJ Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 1976; 25: 2073–7.
Fowler CJ, Callingham BA, Mantle TJ, Tipton KF. The effect of lipophilic compounds upon the activity of rat liver mitochondrial monoamine oxidase -A and -B. Biochemical Pharmacol 1980; 29: 1177–83.
Yasuhara, H, Wada I, Sakamoto K. Inhibitory effects of B-blockers and local anaesthetics on monoamine oxidase and their membrane effects.In: Monoamine oxidase: basic and clinical frontiers. Kamija K, Usdin E, Nagatsu T (Eds). Excerpta Medica, Amsterdam 1982; 251–61.
Roth JA. Inhibition of human brain type B monoamine oxidase by tricyclic psychoactive drugs. Mol Pharmacol 1978; 14: 164–71.
Roizen MF. Anesthetic implications of concurrent disease.In: Miller RD (Ed). Anesthesia. 2nd ed. New York: Churchill Livingstone, 1986; 331–2.
Perks ER. Monoamine oxidase inhibitors. Anaesthesia 1964; 19: 376–86.
Davidson J, Zung WW, Walker JI. Practical aspects of MAI inhibitor therapy. J Clin Psychiatry 1984; 45 (sec. 2): 81–4.
Jenkins LC, Graves HB. Potential hazards of psychoactive drugs in association with anaesthesia. Can Anaesth Soc J 1965; 12: 121–8.
Brown TCK, Cass NM. Beware - the use of MAO inhibitors is increasing again. Anaesth Intensive Care 1979; 7: 65–8.
Sheean DV, Claycomb JB, Kouretas N. Monoamine oxidase inhibitors: prescription and patient management. Int J Psych Med 1980-1981; 10(2): 99–121.
Evans-Prosser CDG. The use of pethidine and morphine in the presence of monoamine oxidase inhibitors. Br J Anaesth 1968; 40: 279–82.
Wong KC, Puerto AX, Puerto BA, Blatnick RA. Influence of imipramine and pargyline on the arrythmogenicity of epinephrine during halothane, enflurane or methoxyflurane anaesthesia in dogs. Life Sciences 1980; 27: 2675–8.
Braverman B, Ivankovich AD, McCarthy R. The effects of fentanyl and vasopressors on anaesthetized dogs receiving MAO inhibitors. Anesth Analg 1984; 63: 192 (Abs).
El-Ganzouri AR, Ivankovich AD, Braverman B, McCarthy R. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg 1985; 64: 592–6.
Michaels I, Serrings M, Shier N, Barash PG. Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors. Anesth Analg 1984; 63: 1041–4.
Ayd F. Should monoamine oxidase inhibitors be discontinued preoperatively? Int. Drug Therapy Newsletter 1986; 21(6): 24.
Wong KC. Preoperative discontinuation of monoamine oxidase inhibitor therapy: an old wives tale? Sem Anes 1986; 5: 145–8.
Sides CA. Hypertension during anaesthesia with monoamine oxidase inhibitors. Anaesthesia 1987; 42: 633–5.
Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Int Med 1955; 42: 417–24.
Papp C, Benaim S. Toxic effects of iproniazid in a patient with angina. Br Med J 1958; 2: 1070–2.
Shee JC. Dangerous potentiation of pethidine by iproniazid and its treatment. Br Med J 1960; 2: 507–9.
Palmer H. Potentiation of pethidine. Br Med J 1960; 2: 944.
Taylor DC. Alarming reaction to pethidine in patients on phenelzine. Lancet 1962; 2: 401–2.
Denton PH, Borell VM, Edwards NV. Dangers of monoamine oxidase inhibitors. Br Med J 1962; 2:1752.
Spencer GT, Smith SE. Dangers of monoamine oxidase inhibitors. Br Med J 1963; 1: 750.
Churchill-Davidson HC. Anaesthesia and monoamineoxidase inhibitors. Br Med J 1965; 1: 520.
Rogers KJ, Thornton JA. The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice. Br J Pharmacol 1969; 36: 470–80.
Dostert P. Myth and reality of the classical MAO inhibitors. Reasons for seeking a new generation.In: Tipton KF, Dostert P, Benedetti MS (Eds). Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press, 1984: 9–25.
Vickers MD. Anaesthesia and MAO inhibitors. Br Med J 1965; 1: 1126.
Penn RG, Rogers KJ. Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with an MAO. Br J Pharmacol 1971; 42: 485.
Brown DD, Waldron DH. An unusual reaction to tranylcypromine. Practitioner 1962; 189: 83–5.
Baldessarini RJ. Drugs and the treatment of psychiatric disorders.In: Gillman AC, Goodman LS, Gilman A (Eds). The pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980: 427–30.
Youssef MS, Wilkinson PA. Epidural fentanyl and monoamine oxidase inhibitors. Anaesthesia 1988; 43: 210–2.
Hirsch MS, Walter RM, Hasterlik RJ. Subarachnoid hemorrhage following ephedrine and MAO inhibitor. JAMA 1965; 194: 1259.
Cousins MJ, Maltby JR. Delayed recovery of sympathetic transmission following ten years MAO inhibition. Br J Anaesth 1971; 43: 803–6.
Hirsch MS, Walter RM, Hauterlik RJ. Subarachnoid hemorrhage following ephedrine and MAO inhibitors. JAMA 1965; 194: 1259.
Horler AR, Wayne NA. Hypertensive crises due to pargyline and metaraminol. Br Med J 1965; 2: 460–1.
Mason A. Fatal reaction associated with tranylcypromine and methylamphetamine. Lancet 1962; 1: 173–7.
Cuthbert MF, Greenberg MP, Morley SW. Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J 1969; 1: 404–6.
Blackwell B. Hypertensive crisis due to MAO inhibitors. Lancet 1963; 2: 849–51.
Elis J, Laurence Dr, Manie H, Prichard BNC. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on the blood pressure. Br Med J 1967; 2: 75–8.
Hunter KR, Boakes AJ, Laurence Dr, Sterne GM. Monoamine oxidase inhibitors and L-dopa. Br Med J 1970; 3: 338.
Horwitz D, Goldberg LI, Sjoerdsma A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitor in man. J Lab Clin Med 1960; 56: 747–53.
Janowsky EC, Risen SC, Janowsky DS. Psychotropic agents.In: Smith TY, Miller RD, Corbascio AN (Eds). Drug Interactions in Anesthesia. Philadelphia: Lea and Febinger, 1981: 177–95.
Jacobson J. A review of the danger of monoamine oxidase inhibitors, with special reference to anesthesia. S Afr Med J 1965; 39: 10–4.
Boakes AJ, Teoh PC, Barar FKS, Benedikter LT, Prichard BNC. Interaction between sympathomimetic amines and antidepressant agents in man. B Med J 1973; 1: 311–5.
Wulfsohn NL, Politzer WM. 5-Hydroxytryptamine in anaesthesia. Anaesthesia 1962; 17: 64–8.
Fouts JR,Brodie BB. On the mechanism of drug potentiation by iproniazid. J Pharmacol Exp Ther 1956; 116–480–5.
Gaines GY, Ress DI. Electroconvulsive therapy and anesthetic considerations. Anesth Analg 1986; 65: 1345–56.
Domino EF, Sullivan TS, Buby ED. Barbiturate intoxication in a patient treated with a MAO inhibitor. Am J Psych 1962; 118:941–3.
Bodley PO, Halwax K, Potts L. Low serum pseudocholinesterase levels complicating treatment with phenelzine. Br Med J 1969; 3: 510–2.
Sjoquist F. Psychotropic. (2) Interaction between monoamine oxidase (MAOI) inhibitors and other substances. Proc R Soc Med 1965; 58: 967.
Johnston RR, Eger EI, Wildon C. A comparative interaction of epinephrine with enflurane, isoflurane and halothane in man. Anesth Analg 1976; 55: 709–12.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wells, D.G., Bjorksten, A.R. monoamine oxidase inhibitors revisited. Can J Anaesth 36, 64–74 (1989). https://doi.org/10.1007/BF03010890
Issue Date:
DOI: https://doi.org/10.1007/BF03010890